We retain our positive view on Carasent following the Q1 2026 report. While we seem to have underestimated the underlying OPEX, resulting in us cutting EBITDA-CAPEX, primarily for 2026, the 16% organic ARR growth is solid. Furthermore, the strong customer inflow in Medsum following the LLM change, and the progress in Germany are promising.
LÄS MER
